TY - JOUR
T1 - A distinct dexamethasone-dependent gene expression profile in the lungs of COVID-19 patients
AU - Fahnøe, Ulrik
AU - Ronit, Andreas
AU - Berg, Ronan M G
AU - Jørgensen, Sofie E
AU - Mogensen, Trine H
AU - Underwood, Alexander P
AU - Scheel, Troels K H
AU - Bukh, Jens
AU - Plovsing, Ronni R
N1 - © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America and HIV Medicine Association. All rights reserved. For permissions, please e-mail: [email protected].
PY - 2022/12/13
Y1 - 2022/12/13
N2 - The effects of dexamethasone (DXM) treatment on pulmonary immunity in COVID-19-associated acute respiratory distress syndrome (CARDS) remain insufficiently understood. We performed transcriptomic RNA-seq analysis of bronchoalveolar lavage fluid from 20 mechanically ventilated patients: 12 with CARDS (with or without DXM) and 8 non-COVID-19 critically ill controls. CARDS with DXM was characterized by upregulation of genes related to B-cell and complement pathway activation, antigen presentation, phagocytosis, and FC-γ receptor signaling. Most interferon-stimulated genes were upregulated in CARDS, particularly in CARDS without DXM. In conclusion, DXM treatment was not associated with regulation of proinflammatory pathways in CARDS but with regulation of other local immune responses. Clinical Trials Registration. NCT04354584.
AB - The effects of dexamethasone (DXM) treatment on pulmonary immunity in COVID-19-associated acute respiratory distress syndrome (CARDS) remain insufficiently understood. We performed transcriptomic RNA-seq analysis of bronchoalveolar lavage fluid from 20 mechanically ventilated patients: 12 with CARDS (with or without DXM) and 8 non-COVID-19 critically ill controls. CARDS with DXM was characterized by upregulation of genes related to B-cell and complement pathway activation, antigen presentation, phagocytosis, and FC-γ receptor signaling. Most interferon-stimulated genes were upregulated in CARDS, particularly in CARDS without DXM. In conclusion, DXM treatment was not associated with regulation of proinflammatory pathways in CARDS but with regulation of other local immune responses. Clinical Trials Registration. NCT04354584.
KW - acute respiratory distress syndrome
KW - bronchoalveolar lavage fluid
KW - coronavirus disease 2019
KW - inflammation
KW - interferon stimulated genes
KW - transcriptome profiling
KW - Bronchoalveolar Lavage Fluid
KW - Pneumonia
KW - Humans
KW - Lung
KW - Transcriptome
KW - Dexamethasone/pharmacology
KW - COVID-19/genetics
KW - Respiratory Distress Syndrome/drug therapy
UR - http://www.scopus.com/inward/record.url?scp=85138626207&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiac218
DO - 10.1093/infdis/jiac218
M3 - Journal article
C2 - 35639922
SN - 0022-1899
VL - 226
SP - 2137
EP - 2141
JO - The Journal of infectious diseases
JF - The Journal of infectious diseases
IS - 12
M1 - jiac218
ER -